Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India

Juneja et al., Journal of Basic and Clinical Physiology and Pharmacology, doi:10.1515/jbcpp-2021-0221
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case -142% Improvement Relative Risk Case -6% HCQ for COVID-19  Juneja et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 2,200 patients in India (April - September 2020) Higher severe cases with HCQ (not stat. sig., p=0.59) c19hcq.org Juneja et al., J. Basic and Clinical P.., Jan 2022 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 2,200 healthcare workers in India, 996 taking HCQ prophylaxis, showing no significant differences. There were large differences in the occupation of participants and therefore exposure, and the authors make no adjustments.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of severe case, 141.8% higher, RR 2.42, p = 0.59, treatment 2 of 996 (0.2%), control 1 of 1,204 (0.1%).
risk of case, 6.4% higher, RR 1.06, p = 0.67, treatment 103 of 996 (10.3%), control 117 of 1,204 (9.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Juneja et al., 7 Jan 2022, retrospective, India, peer-reviewed, 9 authors, study period 2 April, 2020 - 3 September, 2020.
This PaperHCQAll
Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India
Proteesh Shivani Juneja, Proteesh Rana, Parvinder Chawla, Rekha Katoch, Kulvir Singh, Shobha Rana, Tamanna Mittal, Bhavnish Kaur, Simranjot Kaur
Journal of Basic and Clinical Physiology and Pharmacology, doi:10.1515/jbcpp-2021-0221
Objectives: The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs. Methods: A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR). Results: About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%). Conclusions: HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs.
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., Prevention and treatment of COVID-19 with hydroxychloroquine (PATCH) investigators. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern Med
Bhattacharyya, Raizada, Nagappa, Tomar, Maurya et al., Chemoprophylaxis of COVID-19 with hydroxychloroquine: a study of health care workers attitude, adherence to regime and side effects, doi:10.1101/2020.06.11.20126359v1
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med
Chen, Li, Lu, Shen, Zhou, Hydroxychloroquine/ Chloroquine as therapeutics for COVID-19: truth under the mystery, Int J Biol Sci
Ferner, Aronson, Chloroquine and hydroxychloroquine in COVID-19, BMJ
Gio, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Hartwig, Siegel, Schneider, Preventability and severity assessment in reporting adverse drug reactions, Am J Hosp Pharm
Jha, Batra, Siddiqui, Yadav, Misra et al., HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers, Indian Heart J
Juneja, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 among HCWs
Rana, Ghadlinge, Singh, Chandane, Khanna, Assessment of knowledge, attitude and practices on the use of hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection among medical doctors: a cross-sectional study, Pharm Biomed Res
Toumi, Biernikiewicz, Liang, Wang, Qiu et al., A critical analysis and review of Lancet COVID-19 hydroxychloroquine study, J Mark Access Health Policy
{ 'indexed': {'date-parts': [[2022, 1, 8]], 'date-time': '2022-01-08T05:59:36Z', 'timestamp': 1641621576398}, 'reference-count': 14, 'publisher': 'Walter de Gruyter GmbH', 'issue': '0', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec id="j_jbcpp-2021-0221_abs_001">\n' ' <jats:title>Objectives</jats:title>\n' ' <jats:p>The use of Hydroxychloroquine (HCQ) prophylaxis has been ' 'recommended by the National task force constituted by the Indian Council of Medical Research ' '(ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers ' '(HCWs). However, this recommendation was based essentially on the preclinical data and ' 'limited clinical experience. The aim of this study was to evaluate the efficacy and safety of ' 'HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec id="j_jbcpp-2021-0221_abs_003">\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>A cross-sectional study was conducted among HCWs of a tertiary care ' 'hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were ' 'followed up to 8\xa0weeks for conversion to COVID-19 positive status and any adverse drug ' 'reaction (ADR).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec id="j_jbcpp-2021-0221_abs_004">\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>About 10.3% of the study participants were tested positive for ' 'COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis ' '(9.7%).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec id="j_jbcpp-2021-0221_abs_005">\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>HCQ was well tolerated at a weekly dose of 400\xa0mg for 8\xa0weeks ' 'but provided no additional benefit in prevention of COVID-19 among HCWs.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1515/jbcpp-2021-0221', 'type': 'journal-article', 'created': {'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T08:28:48Z', 'timestamp': 1641544128000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among ' 'health care workers: a cross-sectional study in a tertiary care hospital in North India'], 'prefix': '10.1515', 'volume': '0', 'author': [ { 'given': 'Shivani', 'family': 'Juneja', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Clinical Pharmacology , Fortis Hospital Mohali , ' 'Mohali , India'}]}, { 'given': 'Proteesh', 'family': 'Rana', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacology, University College of Medical ' 'Sciences , Delhi , India'}]}, { 'given': 'Parvinder', 'family': 'Chawala', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Rekha', 'family': 'Katoch', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Kulvir', 'family': 'Singh', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Shobha', 'family': 'Rana', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Tamanna', 'family': 'Mittal', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Bhavnish', 'family': 'Kaur', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}, { 'given': 'Simaranjot', 'family': 'Kaur', 'sequence': 'additional', 'affiliation': [{'name': 'Fortis Hospital Mohali , Mohali , Punjab , India'}]}], 'member': '374', 'published-online': {'date-parts': [[2022, 1, 7]]}, 'reference': [ { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_001', 'unstructured': 'COVID19 state wise status. Government of India. Available from: ' 'https://www.mygov.in/corona-data/covid19-statewise-status [Accessed 27 ' 'Jun 2020].'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_002', 'unstructured': 'Recommendation for empiric use of hydroxy-chloroquine for prophylaxis of ' 'SARS-CoV-2. Indian Council for Medical Research 2020. Available from: ' 'https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf ' '[Accessed 24 Apr 2020].'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_003', 'doi-asserted-by': 'crossref', 'unstructured': 'Gio, J, Tian, Z, Yang, X. Breakthrough: chloroquine phosphate has\xa0' 'shown apparent efficacy in treatment of COVID-19 associated pneumonia in ' 'clinical studies. Biosci Trends 2020;14:72–3.', 'DOI': '10.5582/bst.2020.01047'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_004', 'unstructured': 'Revised advisory on the use of Hydroxychloroquine (HCQ) as\xa0' 'prophylaxis for COVID-19 infection. Available from: ' 'https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf ' '[Accessed 24 Apr 2020].'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_005', 'doi-asserted-by': 'crossref', 'unstructured': 'Ferner, RE, Aronson, JK. Chloroquine and hydroxychloroquine in COVID-19. ' 'BMJ 2020;369:1432. https://doi.org/10.1136/bmj.m1432.', 'DOI': '10.1136/bmj.m1432'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_006', 'doi-asserted-by': 'crossref', 'unstructured': 'Hartwig, SC, Siegel, J, Schneider, PJ. Preventability and severity ' 'assessment in reporting adverse drug reactions. Am J Hosp Pharm ' '1992;49:2229–32. https://doi.org/10.1093/ajhp/49.9.2229.', 'DOI': '10.1093/ajhp/49.9.2229'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_007', 'unstructured': 'World Health Organization (WHO). Uppsala Monitoring Centre. The use of ' 'the WHO-UMC system for standardized case causality assessment. WHO. ' 'Available from: http://www.who-umc.org/graphics/4409.pdf [Accessed 24 ' 'Jun 2021].'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_008', 'doi-asserted-by': 'crossref', 'unstructured': 'Abella, BS, Jolkovsky, EL, Biney, BT, Uspal, JE, Hyman, MC, Frank, I, et ' 'al.. Prevention and treatment of COVID-19 with hydroxychloroquine ' '(PATCH) investigators. Efficacy and safety of hydroxychloroquine vs ' 'placebo for pre-exposure SARS-CoV-2 prophylaxis among health care ' 'workers: a randomized clinical trial. JAMA Intern Med 2021;181:195–202. ' 'https://doi.org/10.1001/jamainternmed.2020.6319.', 'DOI': '10.1001/jamainternmed.2020.6319'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_009', 'doi-asserted-by': 'crossref', 'unstructured': 'Boulware, DR, Pullen, MF, Bangdiwala, AS, Pastick, KA, Lofgren, SM, ' 'Okafor, EC, et al.. A randomized trial of hydroxychloroquine as ' 'postexposure prophylaxis for COVID-19. N Engl J Med 2020;383:517–25. ' 'https://doi.org/10.1056/nejmoa2016638.', 'DOI': '10.1056/NEJMoa2016638'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_010', 'unstructured': 'Bhattacharyya, D, Raizada, N, Nagappa, B, Tomar, A, Maurya, P, ' 'Chaudhary, A, et al.. Chemoprophylaxis of COVID-19 with ' 'hydroxychloroquine: a study of health care workers attitude, adherence ' 'to regime and side effects. Available from: ' 'https://www.medrxiv.org/content/10.1101/2020.06.11.20126359v1 [Accessed ' '20 Jun 2020].'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_011', 'doi-asserted-by': 'crossref', 'unstructured': 'Rana, P, Ghadlinge, M, Singh, P, Chandane, R, Khanna, A. Assessment of ' 'knowledge, attitude and practices on the use of hydroxychloroquine (HCQ) ' 'as prophylaxis for COVID-19 infection among medical doctors: a ' 'cross-sectional study. Pharm Biomed Res 2021;7:97–104.', 'DOI': '10.18502/pbr.v7i2.7362'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_012', 'doi-asserted-by': 'crossref', 'unstructured': 'Jha, S, Batra, N, Siddiqui, S, Yadav, A, Misra, A, Loomba, M, et al.. ' 'HCQ prophylaxis in COVID-19 did not show any QTc prolongation in ' 'Healthcare workers. Indian Heart J 2021;73:74–6. ' 'https://doi.org/10.1016/j.ihj.2020.11.005.', 'DOI': '10.1016/j.ihj.2020.11.005'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_013', 'doi-asserted-by': 'crossref', 'unstructured': 'Toumi, M, Biernikiewicz, M, Liang, S, Wang, Y, Qiu, T, Han, R. A\xa0' 'critical analysis and review of Lancet COVID-19 hydroxychloroquine ' 'study. J Mark Access Health Policy 2020;8:1809236. ' 'https://doi.org/10.1080/20016689.2020.1809236.', 'DOI': '10.1080/20016689.2020.1809236'}, { 'key': '2022010717003844546_j_jbcpp-2021-0221_ref_014', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen, Y, Li, MX, Lu, GD, Shen, HM, Zhou, J. ' 'Hydroxychloroquine/Chloroquine as therapeutics for COVID-19: truth under ' 'the mystery. Int J Biol Sci 2021;17:1538–46. ' 'https://doi.org/10.7150/ijbs.59547.', 'DOI': '10.7150/ijbs.59547'}], 'container-title': ['Journal of Basic and Clinical Physiology and Pharmacology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.degruyter.com/document/doi/10.1515/jbcpp-2021-0221/xml', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.degruyter.com/document/doi/10.1515/jbcpp-2021-0221/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T17:01:05Z', 'timestamp': 1641574865000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 7]]}, 'references-count': 14, 'journal-issue': {'issue': '0', 'published-online': {'date-parts': [[2022, 1, 7]]}}, 'alternative-id': ['10.1515/jbcpp-2021-0221'], 'URL': 'http://dx.doi.org/10.1515/jbcpp-2021-0221', 'relation': {}, 'ISSN': ['0792-6855', '2191-0286'], 'issn-type': [{'value': '0792-6855', 'type': 'print'}, {'value': '2191-0286', 'type': 'electronic'}], 'subject': ['Drug Discovery', 'Pharmacology', 'General Medicine', 'Physiology'], 'published': {'date-parts': [[2022, 1, 7]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit